tbuckley/cabot-search huggingface dataset:
Mind/Body Medicine: A Journal of Clinical Behavioral Medicine
Authors: Bruce K. Pickens
Journal: JAMA (1997)

The editors of<i>Mind/Body Medicine</i>intend it to be an authoritative source for practicing physicians from diverse specialties, clinical psychologists, nurses, and social workers. In the opening editorial of the first issue they write, "As we broaden our concept of medical care to embrace nondrug and nonsurgical self-care interventions, we need not and should not compromise scientific standards." The journal's subscription form and Web home page (http://socbehmed. org/sbm.sbmmbm.htm) declare it to be "dedicated to the integration of mind/ body interventions into clinical practice and to dissemination of information of direct clinical relevance to practitioners in behavioral Medicine and bioMedicine." This purpose statement continues with "Mind/body approaches consider the interaction of psychological and biological processes in clinical care... [<i>Mind/ Body Medicine</i>] is intended to be the authoritative source for what is and what is not valid in mind/body Medicine because there are many unsubstantiated claims." <i>Mind/Body Medicine</i>has a 24-member multidisciplinary
Evaluation of Patient-Care Protocol Use by Various Providers
Authors: Richard H. Grimm, Kitty Shimoni, William R. Harlan, E. Harvey Estes
Journal: New England Journal of Medicine (1975)

Abstract A symptom-oriented protocol for acute pharyngitis was evaluated in a busy general medical clinic staffed by physicians and graduate and student physician's assistants. We observed significantly improved performance by all providers in collection of medical data, utilization of laboratory tests, and appropriate use of antibiotics after introduction of the protocol. Patient charges were less when the protocol was used, but these savings were offset partially by the cost of audit. Compliance with and acceptance of the protocol differed among the various health providers, with physicians demonstrating significantly lower levels than nonphysicians. Patient-care protocols provide an effective means of monitoring the process of medical care, detecting weakness in supportive clinic services, and affording educational feedback for all health providers. (N Engl J Med 292:507–511, 1975)
Herbert Gaines Langford, MD
Authors: Elise Y. Bittner
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Evaluation of the Obese Patient
Authors: George A. Bray, William T. Dahms, Frank L. Greenway, Molly Marriott, Mark Molitch, Richard Atkinson
Journal: JAMA (1976)

IN A previous issue, 1 we provided an algorithm for use in evaluating the cases of obese patients. To determine the frequency of abnormalities among the various measurements in this algorithm, we have evaluated a large group of obese patients, and the results are reported in this article.  Measures and Procedures  Obese patients telephoning the Harbor General Hospital in response to an article in the daily newspaper were offered the opportunity to obtain a free medical evaluation in our Obesity Clinic. Each patient was seen once, on one of three separate weekends (Table 1). They were requested not to eat for 12 hours before the clinic appointments. Upon arrival, they filled out questionnaires concerning their present and past history of obesity. A blood sample was obtained on each patient, and those attending the third clinic received 40 gm/ sq m of a dextrose solution. A second blood sample was drawn
New research rankings put Oxford, Cambridge, and King's College London as top three in UK
Authors: G. Iacobucci
Journal: BMJ (2014)

Oxford is the UK’s top university for academic research relating to clinical medicine, an analysis of new rankings has shown.

An analysis of the latest rankings from the Research Excellence Framework1 by Times Higher Education 2 showed that the University of Oxford had an overall grade point average of 3.45 against a range of indicators, including the proportion of the research output that was deemed to be world leading.

The University of Cambridge was just behind with an average rating of 3.43, followed by King’s College, London, with an average of …
A psychiatrist in the family
Authors: K.-M. Mueller
Journal: BMJ (1998)

I was in my first post in psychiatry and went to see my parents. My mother was unwell. I had seen her in this state many times but I had not understood. Her mood was low and she talked about hanging herself. I suggested that she should see her GP but she refused. I proposed a psychiatric appointment. She did not want to know: “Hospital? I'll run away.” I talked with my father. “No psychiatrists,” he said. “I took her once and the psychiatrist blamed me. She always gets depressed in winter and recovers in the spring without treatment.” My sisters asked: “Can't you help her? Why do we have a psychiatrist in the family? Don't you know how to get her better?”

I did not think it right for a daughter to treat her mother, especially for a psychiatric …
A Role for HPV16 E5 in Cervical Carcinogenesis
Authors: John P. Maufort, Anny Shai, Henry C. Pitot, Paul F. Lambert
Journal: Cancer Research (2010)

Abstract A subset of the mucosotropic human papillomaviruses (HPV), including HPV16, are etiologic agents for the vast majority of cervical cancers, other anogenital cancers, and a subset of head and neck squamous cell carcinomas. HPV16 encodes three oncogenes: E5, E6, and E7. Although E6 and E7 have been well-studied and clearly shown to be important contributors to these cancers, less is known about E5. In this study, we used E5 transgenic mice to investigate the role of E5 in cervical cancer. When treated for 6 months with estrogen, a cofactor for cervical carcinogenesis, E5 transgenic mice developed more severe neoplastic cervical disease than similarly treated nontransgenic mice, although no frank cancers were detected. In addition, E5 when combined with either E6 or E7 induced more severe neoplastic disease than seen in mice expressing only one viral oncogene. Prolonged treatment of E5 transgenic mice with exogenous estrogen uncovered an ability of E5 to cause frank cancer. These data indicate that E5 acts as an oncogene in the reproductive tracts of female mice. Cancer Res; 70(7); 2924–31
Erythropoietin: when liability becomes asset in neurovascular repair
Authors: Maria B. Grant, Michael E. Boulton, Alexander V. Ljubimov
Journal: Journal of Clinical Investigation (2008)

Erythropoietin (Epo) leads to the proliferation and differentiation of erythroid precursors, but is also involved in diverse nonhematopoietic biological functions. In this issue of the JCI, Chen, Smith, and colleagues demonstrate that the temporal expression of Epo is critical for determining whether physiological or pathological repair occurs following neurovascular retinal injury in the oxygen-induced retinopathy neonatal mouse model (see the related article beginning on page 526). The pleiotrophic properties of Epo make it a likely novel therapy for treatment of neurovascular damage, but the timing of its use must be carefully considered to prevent untoward effects.
Long-Term Reduction of Serum Cholesterol Levels of Patients with Atherosclerosis by Small Doses of Neomycin
Authors: PAUL SAMUEL, CHARLES M. HOLTZMAN, JANE GOLDSTEIN
Journal: Circulation (1967)

The effect and tolerance of long-term oral administration of small doses of neomycin as a serum cholesterol reducing agent has been investigated. Sixteen patients were given neomycin sulfate orally for periods varying from 12 to 40.1 months, following control periods of 2.6 to 14.6 months. After an initial daily dose of 2 g of neomycin, the daily dose was varied between 0.5 and 2 g according to response. Average total serum cholesterol concentrations decreased in each of the 16 patients by 15 to 32%; the average decrease for the group was 22%. The difference was statistically significant in each patient at the 0.1% level. Serum cholesterol concentrations were maintained at the lower plateau as long as the drug was given. In an additional patient, after administration of neomycin for 2 months there was no change in serum cholesterol concentrations and the study was discontinued. Another developed severe diarrhea, nausea, and abdominal cramps during the first week of the study, so that medication was interrupted. No other serious side effects occurred. During the first 2 weeks of medication eight of the 16 patients experienced mild diarrhea or abdominal cramps or both which subsided spontaneously during continued medication. Physical examinations were carried out, kidney and liver functions remained normal, and pathogens were not grown from stool cultures.
ACUTE HEMORRHAGIC JAUNDICE OF EPIDEMIC NATURE IN NEW YORK CITY
Authors: DAN H. WITT
Journal: JAMA (1922)

During the latter part of the years 1919 and 1920, there were admitted to Bellevue Hospital a number of patients with acute hemorrhagic jaundice. The disease, which previously had not been recorded in the Second Medical Division, occurred in epidemic form, usually appearing in December and in the early part of January. Sixteen of the cases in which admission occurred during a period beginning the middle of December, 1919, have been reported by Dr. Douglas Symmers,<sup>1</sup>with special emphasis on the symptomatology and pathology. In view of the fact that he was unable to produce the disease in animals, he was inclined to regard the condition as a toxic process. The purpose of the present paper is to report eleven additional cases in the Second Medical Division of Bellevue Hospital. In Dr. Symmers' group of sixteen cases, the severity of the disease was most pronounced. In general, his cases
Reversal of Heparin Anticoagulation by Recombinant Platelet Factor 4 in Humans
Authors: Gregory J. Dehmer, Melrose Fisher, David A. Tate, Steve Teo, Eric M. Bonnem
Journal: Circulation (1995)

Protamine is used to reverse the anticoagulant effects of heparin, but it can have important side effects. Platelet factor 4 (PF4) is a protein found in platelet alpha granules that binds to and thereby neutralizes heparin. We evaluated the safety and effectiveness of intravenous recombinant PF4 to neutralize heparin anticoagulation after cardiac catheterization in a phase 1, open-label trial.The study group consisted of 18 patients having diagnostic cardiac catheterization. Heparin (5000 U) was given after vascular access was obtained. In the first 12 patients, additional heparin was given at the conclusion of the procedure so that all patients had activated coagulation times > 300 seconds before rPF4 was given. Three patients each received 0.5, 1.0, 2.5, or 5.0 mg/kg rPF4 over a period of 3 minutes at the conclusion of the catheterization procedure. In 6 additional patients, extra heparin was not given at the conclusion of the procedure, and 1.0 mg/kg rPF4 was given. Hemodynamic measurements, cardiac output, and serial blood tests were performed 5, 10, 20, and 30 minutes after rPF4 and then into the next 24 hours. There were no serious side effects in any patient, despite transient rPF4 levels as high as 14,870 ng/mL in the patients receiving 5.0 mg/kg. One patient receiving 2.5 mg/kg had a slight transient rise in liver enzymes possibly related to the rPF4. There were no important hemodynamic effects of rPF4 administration at any dose used. Doses of 2.5 and 5.0 mg/kg were uniformly effective in reversing the anticoagulant effect of heparin. At lower doses, rPF4 neutralized the effects of heparin in most but not all patients. Pharmacokinetic analysis suggested a monophasic and one-compartment clearance of the PF4-heparin complex. No neutralizing factors to rPF4 were detected in the samples collected 7 days after dosing.rPF4, in doses ranging from 0.5 to 5.0 mg/kg over 3 minutes, had no serious side effects. Given in sufficient amounts, rPF4 can completely and rapidly reverse the anticoagulant effects of heparin.
Acute lymphoblastic leukemia with t(4;11) in children 1 year and older: The ‘big sister’ of the infant disease?
Authors: G Mann, G Cazzaniga, V H J van der Velden, T Flohr, E Csinady, M Paganin, A Schrauder, A M Dohnal, M Schrappe, A Biondi, H Gadner, J J M van Dongen, E R Panzer-Grümayer
Journal: Leukemia (2007)
Autologous apoptotic cells preceding transplantation enhance survival in lethal murine graft-versus-host models
Authors: Mareike Florek, Emanuela I. Sega, Dennis B. Leveson-Gower, Jeanette Baker, Antonia M. S. Müller, Dominik Schneidawind, Everett Meyer, Robert S. Negrin
Journal: Blood (2014)
William Henry Welch and the Heroic Age of American Medicine
Authors: Claude E. Welch
Journal: JAMA (1994)

Johns Hopkins, a rich Baltimore merchant, left the largest philanthropic gift in the history of the United States when he died in 1873. Nearly $7 million were divided equally between the prospective Johns Hopkins University and The Johns Hopkins Hospital; the Medical School was linked to both of them. He thereby initiated a revolution in American medical education and medical care. A few individuals were responsible for these rapid developments. President Gilman, the first president of the Hopkins, and William Henry Welch, a young pathologist and dean of the medical school, were scientists. Sir William Osler was a great humanist and clinician. William S. Halsted developed meticulous surgical techniques in the laboratory as well as the operating theater. Howard A. Kelly was a dextrous, capable surgeon. The last major architect was Abraham Flexner, who, in 1910, delivered his kiss of death to half of the medical schools in the country
Biosafety in Ex Vivo Gene Therapy and Conditional Ablation of Lentivirally Transduced Hepatocytes in Nonhuman Primates
Authors: Olivier Menzel, Jacques Birraux, Barbara E Wildhaber, Caty Jond, Françoise Lasne, Walid Habre, Didier Trono, Tuan H Nguyen, Christophe Chardot
Journal: Molecular Therapy (2009)

Ex vivo gene therapy is an interesting alternative to orthotopic liver transplantation (OLT) for treating metabolic liver diseases. In this study, we investigated its efficacy and biosafety in nonhuman primates. Hepatocytes isolated from liver lobectomy were transduced in suspension with a bicistronic liver-specific lentiviral vector and immediately autotransplanted (SLIT) into three cynomolgus monkeys. The vector encoded cynomolgus erythropoietin (EPO) and the conditional suicide gene herpes simplex virus-thymidine kinase (HSV-TK). Survival of transduced hepatocytes and vector dissemination were evaluated by detecting transgene expression and vector DNA. SLIT was safely performed within a day in all three subjects. Serum EPO and hematocrit rapidly increased post-SLIT and their values returned to baseline within about 1 month. Isoforms of EPO detected in monkeys' sera differed from the physiological renal EPO. In liver biopsies at months 8 and 15, we detected EPO protein, vector mRNA and DNA, demonstrating long-term survival and functionality of transplanted lentivirally transduced hepatocytes. Valganciclovir administration resulted in complete ablation of the transduced hepatocytes. We demonstrated the feasibility and biosafety of SLIT, and the long term (>1 year) functionality of lentivirally transduced hepatocytes in nonhuman primates. The HSV-TK/valganciclovir suicide strategy can increase the biosafety of liver gene therapy protocols by safely and completely ablating transduced hepatocytes on demand.
Abstract 5413: Maximal Power Design and Analysis of Drug Combination Studies: Applications to Vorinostat with Cytosine Arabinoside and Etoposide and Other Combination Studies
Authors: Hong-Bin Fang, Douglas D. Ross, Martin J. Edelman, Edward A. Sausville, Wei Li, Ming T. Tan
Journal: Cancer Research (2010)

Abstract Drug combinations are the hallmark of cancer therapy. Preclinical experiments on multi-drug combinations are important steps to bring the therapy to clinic. A statistical approach for evaluating the joint effect of the combination is necessary because even in vitro experiments often demonstrate significant variation in dose-effect. Such variation needs to be accounted for in the experimental design and analysis. Our research has developed a maximal power (MP) design and interaction index surface (IIS) analysis methods for in vitro and in vivo (e.g., xenograft) combination studies so that the joint effect of a combination can be estimated efficiently and the most synergistic combination can be identified. We demonstrate that these statistical methods and software have resulted in the identification of highly synergistic dose combinations that could have been missed with classic methods. The first study is the combination of vorinostat (suberoylanilide hydroxamic acid) combined with ara-C and with etoposide in leukemia cell lines. The doses in the experiment were generated by the MP design and the data analyzed using the IIS approach so that synergistic, additive and antagonistic interaction dose regions are identified. Cytotoxic antagonism resulted when vorinostat was combined concomitantly with ara-C; however, when vorinostat was given first followed by a drug-free interval before ara-C treatment, this sequential combination was mostly synergistic. Etoposide combined with vorinostat was additive to synergistic, and the synergism became more pronounced when etoposide was given post a drug-free interval after vorinostat. These findings are used in designing the CTEP trial (NCI 6829: Phase I trial of vorinostat in combination with cytarabine and etoposide in patients with advanced acute leukemia and high-risk myelodysplastic syndromes, PI: Gojo/Ross). The interim results on toxicity and response have been consistent with the model. Another study utilized a novel thiazolidine compound plus Sorafnib where initial experiments using classic methods failed to identify synergistic combinations. Subsequent experiments using the MP methodologies demonstrated significant synergistic drug combinations. The SynStat R program for the design and analysis of drug synergy is available at http://www.umgcc.org/research/biostat_software.htm). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 5413.
A Genomic Classifier Improves Prediction of Metastatic Disease Within 5 Years After Surgery in Node-negative High-risk Prostate Cancer Patients Managed by Radical Prostatectomy Without Adjuvant Therapy
Authors: Eric A. Klein, Kasra Yousefi, Zaid Haddad, Voleak Choeurng, Christine Buerki, Andrew J. Stephenson, Jianbo Li, Michael W. Kattan, Cristina Magi-Galluzzi, Elai Davicioni
Journal: European Urology (2014)
MCP-1 induces a sustained arteriogenic response in ApoE mice but accelerates atherosclerotic plaque development
Authors: Niels van Royen, Imo Hoefer, Markus Boettinger, Jing Hua, Sebastian Grundmann, Michiel Voskuil, Bode Christoph, Wolfgang Schaper, Ivo R. Buscchmann, Jan J. Piek
Journal: Journal of the American College of Cardiology (2003)
Centrogenic pulmonary hemorrhagic edema induced by cerebral compression in rats. Mechanism of volume and pressure loading in the pulmonary circulation.
Authors: H I Chen, J F Liao, L Kuo, S T Ho
Journal: Circulation Research (1980)

In anesthetized and vagotomized rats, an intense cerebral compression (CC) by intracranial placement of a space-occupying mass evoked systemic arterial hypertension (SAH), pulmonary venous hypertension (PVH), and pulmonary hemorrhagic edema (PHE) in 2-3 minutes.Observation of the regional weight changes revealed an acute increase in pulmonary blood volume with a decrease in the volume of the systemic vascular beds.With chronically instrumented flow probes, we demonstrated that the overall pattern of imbalance in right and left cardiac outputs was characterized by an immediate fall in aortic flow by 52% accompanying a slower decline in pulmonary arterial flow.In 10 rats with a right heart bypass (venous return to reservoir and constant pulmonary inflow), CC produced severe PVH and PHE associated with SAH, reservoir volume reduction, and no significant change in pulmonary vascular resistance.The increases in left atrial pressure and lung index (lung: body weight x 100) were much greater than those obtained with natural circulation.In 20 left heart-bypassed rats (constant aortic flow either with or without a reservoir between the left atrium and a roller pump), CC induced SAH, whereas no significant changes occurred in the lungs.The lung index was not different from the normal value.The results indicate that neurogenic constriction of the systemic capacitance vessels to favor venous return is not an important hemodynamic event in the centrogenic pulmonary pathology.Pulmonary volume loading leading to pulmonary hypertension and PHE is evoked principally by a dramatic pulmonary hypertension decrease in left ventricular output due to ventricular strain in the face of an intense arteriolar constriction.
Activated complement components and complement activator molecules on the surface of cell-derived microparticles in patients with rheumatoid arthritis and healthy individuals
Authors: E. Biro, R. Nieuwland, P. P Tak, L. M Pronk, M. C L Schaap, A. Sturk, C E. Hack
Journal: Annals of the Rheumatic Diseases (2007)

In vitro, microparticles can activate complement via the classical pathway. If demonstrable ex vivo, this mechanism may contribute to the pathogenesis of rheumatoid arthritis (RA). We therefore investigated the presence of activated complement components and complement activator molecules on the surface of cell-derived microparticles of RA patients and healthy individuals.
Another Tobacco Report Proposed
Authors: Charles Marwick
Journal: JAMA (1988)

BURIED in massive federal tax law corrections are five paragraphs requesting the surgeon general of the Public Health Service to study the health care costs of smoking. Put into the House bill by Representative Michael A. Andrews (D, Texas), the legislation calls for a report to be sent to Congress every two years. The study would also compare smokers with those passively exposed to tobacco and with nonsmokers and would survey incidence of smoking in the United States. The House passed its version of the tax revision bill in August. A similar bill has yet to be acted upon by the Senate. The legislation has been opposed by a number of senators from tobacco-growing states. But this opposition is not the central problem. There are significant differences between the two bills in terms of the tax revisions they contain. These could slow passage of the Senate bill, particularly as there